- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06155643
EKO SENSORA: Detecting Clinically Significant Murmurs (EkoNM)
The Eko Artificial Intelligence (AI) has primarily been evaluated in the primary care setting. The digital stethoscope records a phonocardiogram of heart sounds of the patient and uses machine learning artificial intelligence to identify if there are abnormalities present (Eko Health, 2023).
The Eko SENSORA will be tested in the emergency department. Chest pain, fatigue, shortness of breath and syncope are all symptoms that could indicate a cardiac dysfunction.
The hypothesis is that this device will allow us increased ability to detect valvular heart disease that is clinically significant.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Monique Luna, MS
- Phone Number: 2699838679
- Email: monique.allen@corewellhealth.org
Study Locations
-
-
Michigan
-
Saint Joseph, Michigan, United States, 49085
- Recruiting
- Corewell Health Lakeland
-
Contact:
- Matthew Hysell, MD
- Email: matthew.hysell@corewellhealth.org
-
Contact:
- Amanda Borchardt, PhD
- Phone Number: 2699838679
- Email: amanda.borchardt@corewellhealth.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Chief complaint of chest pain, shortness of breath, difficulty breathing, or syncope/near-syncope.
- Patients with chief complaint of Weakness would be eligible if over the age of 50 and have a history of at least two of hypertension, BMI>/= 30, diabetes, hyperlipidemia, atrial fibrillation, heart attack, stroke/Transient ischemic attack, prior cardiac surgery or angiography
Exclusion Criteria:
- Contact isolation patients
- Pediatric patients under the age of 18
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Eko Device
Patients with cardiac risk factors
|
The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded.
The recording is then uploaded by the device using wi-fi to the AI program for analysis.
It does not carry patient identifiers.
The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of new clinically significant heart murmurs detected
Time Frame: through study completion, an average of 90 days
|
through study completion, an average of 90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of echocardiograms ordered
Time Frame: through study completion, an average of 90 days
|
through study completion, an average of 90 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1635
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.